The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Open accessAbstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for treatment of diabetes, have been shown to possess a favorable metabolic profile and to significantly reduce atherosclerotic events, hospitalization for heart failure, cardiovascular and total mortality, and progression of chronic kidney disease. Although initially considered to be only glucose-lowering agents, the effects of SGLT2i have expanded far beyond that, and their use is now being studied in the treatment of heart failure and chronic kidney disease, even in patients without diabetes. It is therefore critical for cardiologists, diabetologists, nephrologists, and primary care physicians to be familiar with this drug class. This first part of this 2-part review provides an overview of the current understanding of the mechanisms of the cardio-metabolic-renal benefits of SGLT2i. The second part summarizes the recent clinical trials of SGLT2i.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Self-citationThe ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
Youm, Y.-H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., D'Agostino, D., Planavsky, N., Lupfer, C., Kanneganti, T. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3804 · Cited by 2,172
Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity
Jia, G., Hill, M. A., & Sowers, J. R. (2018) · Circulation Research · doi:10.1161/circresaha.117.311586 · Cited by 1,807
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Prevalence of Type 1 and Type 2 Diabetes Among Children and Adolescents From 2001 to 2009
Dabelea, D., Mayer-Davis, E. J., Saydah, S., Imperatore, G., Linder, B., Divers, J., Bell, R., Badaru, A., Talton, J. W., Crume, T., et al. (2014) · JAMA · doi:10.1001/jama.2014.3201 · Cited by 1,412
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
Diabetic Cardiomyopathy: What Is It and Can It Be Fixed?
Dillmann, W. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.314665 · Cited by 669
Kenny, H. C., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 660
Santos-Gallego, C. G., Requena-Ibanez, J. A., San Antonio, R., Ishikawa, K., Watanabe, S., Picatoste, B., Flores, E., Garcia-Ropero, A., Sanz, J., Hajjar, R. J., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.056 · Cited by 651
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639
Kanai, Y., Lee, W. S., You, G., Brown, D., & Hediger, M. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116972 · Cited by 630
Uthman, L., Baartscheer, A., Bleijlevens, B., Schumacher, C. A., Fiolet, J. W. T., Koeman, A., Jancev, M., Hollmann, M. W., Weber, N. C., Coronel, R., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4509-7 · Cited by 610
The sodium/glucose cotransport family SLC5
Wright, E. M., & Turk, E. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1202-0 · Cited by 537
Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13126 · Cited by 499
Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-28 · Cited by 470
Heerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019) · Diabetologia · doi:10.1007/s00125-019-4859-4 · Cited by 457
Nonalcoholic Fatty Liver Disease and the Heart
Stahl, E. P., Dhindsa, D. S., Lee, S. K., Sandesara, P. B., Chalasani, N. P., & Sperling, L. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.050 · Cited by 439
Empagliflozin Increases Cardiac Energy Production in Diabetes
Verma, S., Rawat, S., Ho, K. L., Wagg, C. S., Zhang, L., Teoh, H., Dyck, J. E., Uddin, G. M., Oudit, G. Y., Mayoux, E., et al. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.07.006 · Cited by 386
The effect of dapagliflozin treatment on epicardial adipose tissue volume
Sato, T., Aizawa, Y., Yuasa, S., Kishi, S., Fuse, K., Fujita, S., Ikeda, Y., Kitazawa, H., Takahashi, M., Sato, M., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0658-8 · Cited by 378
Ye, Y., Bajaj, M., Yang, H.-C., Perez-Polo, J. R., & Birnbaum, Y. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6725-2 · Cited by 368
Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy
Marwick, T. H., Ritchie, R., Shaw, J. E., & Kaye, D. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.019 · Cited by 365
The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense
Horton, J. L., Davidson, M. T., Kurishima, C., Vega, R. B., Powers, J. C., Matsuura, T. R., Petucci, C., Lewandowski, E. D., Crawford, P. A., Muoio, D. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124079 · Cited by 364
Canagliflozin slows progression of renal function decline independently of glycemic effects
Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030278 · Cited by 361
Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target
Santer, R., & Calado, J. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04010609 · Cited by 343
Glucose Metabolism in Cardiac Hypertrophy and Heart Failure
Tran, D. H., & Wang, Z. V. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012673 · Cited by 335
Montaigne, D., Marechal, X., Coisne, A., Debry, N., Modine, T., Fayad, G., Potelle, C., El Arid, J.-M., Mouton, S., Sebti, Y., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.008476 · Cited by 322
Bonnet, F., & Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.09.005 · Cited by 308
Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria
Santer, R., Kinner, M., Lassen, C. L., Schneppenheim, R., Eggert, P., Bald, M., Brodehl, J., Daschner, M., Ehrich, J. H. H., Kemper, M., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000092790.89332.d2 · Cited by 305
Kidokoro, K., Cherney, D. Z. I., Bozovic, A., Nagasu, H., Satoh, M., Kanda, E., Sasaki, T., & Kashihara, N. (2019) · Circulation · doi:10.1161/circulationaha.118.037418 · Cited by 283
Sano, M., & Goto, S. (2019) · Circulation · doi:10.1161/circulationaha.118.038881 · Cited by 278
The Discovery of Insulin: An Important Milestone in the History of Medicine
Vecchio, I., Tornali, C., Bragazzi, N. L., & Martini, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00613 · Cited by 272
Diabetes, heart failure, and renal dysfunction: The vicious circles
Braunwald, E. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.003 · Cited by 254
Self-citationLatva-Rasku, A., Honka, M.-J., Kullberg, J., Mononen, N., Lehtimäki, T., Saltevo, J., Kirjavainen, A. K., Saunavaara, V., Iozzo, P., Johansson, L., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1569 · Cited by 253
Kario, K., Okada, K., Kato, M., Nishizawa, M., Yoshida, T., Asano, T., Uchiyama, K., Niijima, Y., Katsuya, T., Urata, H., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037076 · Cited by 251
Sha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S. ‐., Sica, D., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12322 · Cited by 249
Cherney, D. Z. I., Cooper, M. E., Tikkanen, I., Pfarr, E., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Lund, S. S. (2018) · Kidney International · doi:10.1016/j.kint.2017.06.017 · Cited by 243
Mancini, S. J., Boyd, D., Katwan, O. J., Strembitska, A., Almabrouk, T. A., Kennedy, S., Palmer, T. M., & Salt, I. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-23420-4 · Cited by 240
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Zelniker, T. A., & Braunwald, E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.040 · Cited by 236
Self-citationSGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms
Osataphan, S., Macchi, C., Singhal, G., Chimene-Weiss, J., Sales, V., Kozuka, C., Dreyfuss, J. M., Pan, H., Tangcharoenpaisan, Y., Morningstar, J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123130 · Cited by 228
Mustroph, J., Wagemann, O., Lücht, C. M., Trum, M., Hammer, K. P., Sag, C. M., Lebek, S., Tarnowski, D., Reinders, J., Perbellini, F., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12336 · Cited by 225
Empagliflozin directly improves diastolic function in human heart failure
Pabel, S., Wagner, S., Bollenberg, H., Bengel, P., Kovács, Á., Schach, C., Tirilomis, P., Mustroph, J., Renner, A., Gummert, J., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1328 · Cited by 224
Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
Matthews, V. B., Elliot, R. H., Rudnicka, C., Hricova, J., Herat, L., & Schlaich, M. P. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001434 · Cited by 222
Chagnac, A., Zingerman, B., Rozen-Zvi, B., & Herman-Edelstein, M. (2019) · Nephron · doi:10.1159/000499486 · Cited by 210
Wanner, C., Heerspink, H. J. L., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., Hantel, S., Woerle, H.-J., Broedl, U. C., von Eynatten, M., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018010103 · Cited by 209
Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD
Schneider, M. P., Raff, U., Kopp, C., Scheppach, J. B., Toncar, S., Wanner, C., Schlieper, G., Saritas, T., Floege, J., Schmid, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060662 · Cited by 195
Soga, F., Tanaka, H., Tatsumi, K., Mochizuki, Y., Sano, H., Toki, H., Matsumoto, K., Shite, J., Takaoka, H., Doi, T., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0775-z · Cited by 192
Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy
Lee, Y. H., Kim, S. H., Kang, J. M., Heo, J. H., Kim, D.-J., Park, S. H., Sung, M., Kim, J., Oh, J., Yang, D. H., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00565.2018 · Cited by 189
Uthman, L., Baartscheer, A., Schumacher, C. A., Fiolet, J. W. T., Kuschma, M. C., Hollmann, M. W., Coronel, R., Weber, N. C., & Zuurbier, C. J. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01575 · Cited by 188
SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1
Novikov, A., Fu, Y., Huang, W., Freeman, B., Patel, R., van Ginkel, C., Koepsell, H., Busslinger, M., Onishi, A., Nespoux, J., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00462.2018 · Cited by 186
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
Karg, M. V., Bosch, A., Kannenkeril, D., Striepe, K., Ott, C., Schneider, M. P., Boemke-Zelch, F., Linz, P., Nagel, A. M., Titze, J., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0654-z · Cited by 182
Adingupu, D. D., Göpel, S. O., Grönros, J., Behrendt, M., Sotak, M., Miliotis, T., Dahlqvist, U., Gan, L.-M., & Jönsson-Rylander, A.-C. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0820-6 · Cited by 172
Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
Matsutani, D., Sakamoto, M., Kayama, Y., Takeda, N., Horiuchi, R., & Utsunomiya, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0717-9 · Cited by 168
Sodium—Glucose cotransporter inhibitors and oxidative stress: An update
Yaribeygi, H., Atkin, S. L., Butler, A. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.26760 · Cited by 167
Zhang, N., Feng, B., Ma, X., Sun, K., Xu, G., & Zhou, Y. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0914-1 · Cited by 167
Basu, D., Huggins, L.-A., Scerbo, D., Obunike, J., Mullick, A. E., Rothenberg, P. L., Di Prospero, N. A., Eckel, R. H., & Goldberg, I. J. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.311339 · Cited by 163
Lim, V. G., Bell, R. M., Arjun, S., Kolatsi-Joannou, M., Long, D. A., & Yellon, D. M. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.10.002 · Cited by 162
Uric Acid as a Biomarker and a Therapeutic Target in Diabetes
Lytvyn, Y., Perkins, B. A., & Cherney, D. Z. I. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.10.013 · Cited by 152
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145
Tanaka, H., Takano, K., Iijima, H., Kubo, H., Maruyama, N., Hashimoto, T., Arakawa, K., Togo, M., Inagaki, N., & Kaku, K. (2017) · Advances in Therapy · doi:10.1007/s12325-016-0457-8 · Cited by 140
Wilcox, C. S., Shen, W., Boulton, D. W., Leslie, B. R., & Griffen, S. C. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007046 · Cited by 139
Neuen, B. L., Ohkuma, T., Neal, B. C., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Li, Q., Jardine, M., Oh, R., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019010064 · Cited by 138
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
Alicic, R. Z., Neumiller, J. J., Johnson, E. J., Dieter, B. P., & Tuttle, K. R. (2019) · Diabetes · doi:10.2337/dbi18-0007 · Cited by 134
Connelly, K. A., Zhang, Y., Visram, A., Advani, A., Batchu, S. N., Desjardins, J., Thai, K., & Gilbert, R. E. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.11.010 · Cited by 126
Woods, T. C., Satou, R., Miyata, K., Katsurada, A., Dugas, C. M., Klingenberg, N. C., Fonseca, V. A., & Navar, L. G. (2019) · American Journal of Nephrology · doi:10.1159/000499597 · Cited by 124
Birnbaum, Y., Bajaj, M., Yang, H., & Ye, Y. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6778-x · Cited by 123
Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
Scheen, A. J. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1165-1 · Cited by 122
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.036 · Cited by 121
Self-citationEl-Daly, M., Pulakazhi Venu, V. K., Saifeddine, M., Mihara, K., Kang, S., Fedak, P. W. M., Alston, L. A., Hirota, S. A., Ding, H., Triggle, C. R., et al. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.06.006 · Cited by 117
Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
Oh, C., Cho, S., Jang, J., Kim, H., Chun, S., Choi, M., Park, S., & Ko, Y. (2019) · Korean Circulation Journal · doi:10.4070/kcj.2019.0180 · Cited by 116
Hess, D. A., Terenzi, D. C., Trac, J. Z., Quan, A., Mason, T., Al-Omran, M. A., Bhatt, D. L., Dhingra, N., Rotstein, O. D., Leiter, L. A., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.015 · Cited by 115
Mayer, G. J., Wanner, C., Weir, M. R., Inzucchi, S. E., Koitka‐Weber, A., Hantel, S., von Eynatten, M., Zinman, B., & Cherney, D. Z. I. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.033 · Cited by 112
Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease
Maruyama, T., Takashima, H., Oguma, H., Nakamura, Y., Ohno, M., Utsunomiya, K., Furukawa, T., Tei, R., & Abe, M. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0212 · Cited by 103
Uthman, L., Nederlof, R., Eerbeek, O., Baartscheer, A., Schumacher, C. A., Buchholtz, N., Hollmann, M. W., Coronel, R., Weber, N. C., & Zuurbier, C. J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz004 · Cited by 99
The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature
Solini, A., Seghieri, M., Giannini, L., Biancalana, E., Parolini, F., Rossi, C., Dardano, A., Taddei, S., Ghiadoni, L., & Bruno, R. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00706 · Cited by 95
Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death
Shibusawa, R., Yamada, E., Okada, S., Nakajima, Y., Bastie, C. C., Maeshima, A., Kaira, K., & Yamada, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-46402-6 · Cited by 90
Prevalence of Diabetes in Adolescents Aged 12 to 19 Years in the United States, 2005-2014
Menke, A., Casagrande, S. S., & Cowie, C. C. (2016) · JAMA · doi:10.1001/jama.2016.8544 · Cited by 82
Abdurrachim, D., Teo, X. Q., Woo, C. C., Chan, W. X., Lalic, J., Lam, C. S. P., & Lee, P. T. H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13536 · Cited by 67
Horie, I., Abiru, N., Hongo, R., Nakamura, T., Ito, A., Haraguchi, A., Natsuda, S., Sagara, I., Ando, T., & Kawakami, A. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.11.016 · Cited by 66
Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes
Mulder, S., Heerspink, H. J. L., Darshi, M., Kim, J. J., Laverman, G. D., Sharma, K., & Pena, M. J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13823 · Cited by 65
Packer, M. (2019) · Circulation · doi:10.1161/circulationaha.119.040909 · Cited by 63
Miyachi, Y., Tsuchiya, K., Shiba, K., Mori, K., Komiya, C., Ogasawara, N., & Ogawa, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-34305-x · Cited by 62
Toto, R. D., Goldenberg, R., Chertow, G. M., Cain, V. A., Stefánsson, B. V., Sjöström, C. D., & Sartipy, P. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.06.007 · Cited by 50
Metabolic Profiling of the Diabetic Heart: Toward a Richer Picture
Sowton, A. P., Griffin, J. L., & Murray, A. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00639 · Cited by 44
Omori, K., Nakamura, A., Miyoshi, H., Takahashi, K., Kitao, N., Nomoto, H., Kameda, H., Cho, K. Y., Takagi, R., Hatanaka, K. C., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.006 · Cited by 42
Cooper, M. E., Inzucchi, S. E., Zinman, B., Hantel, S., von Eynatten, M., Wanner, C., & Koitka‐Weber, A. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.03.432 · Cited by 42
Sodium-glucose cotransporter inhibitors: beyond glycaemic control
Vergara, A., Jacobs-Cachá, C., & Soler, M. J. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz019 · Cited by 37
Lim, V. G., Bell, R., Arjun, S., Kolatsi‐Joannou, M., Long, D. A., & Yellon, D. M. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.05.087 · Cited by 26
Ketone body can be a fuel substrate for failing heart
Nakamura, M., & Sadoshima, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz104 · Cited by 19
Lehrke, M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.023 · Cited by 18
Sodium Glucose Cotransporter 2 Inhibition and the Visualization of Kidney Hemodynamics
Wanner, C. (2019) · Circulation · doi:10.1161/circulationaha.119.040326 · Cited by 7
What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
Evans, M., Morgan, A. R., & Yousef, Z. R. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00678-z · Cited by 5
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., Masoudi, F. A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.022 · Cited by 842
Antar, S. A., Ashour, N. A., Sharaky, M., Khattab, M., Ashour, N. A., Zaid, R. T., Roh, E. J., Elkamhawy, A., & Al-Karmalawy, A. A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115734 · Cited by 622
Metadata
- Authors
- Zelniker, T. A., & Braunwald, E.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 75
- Issue
- 4
- Pages
- 422-434
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W3003546904
- Cited by
- 566
- References
- 103
- FWCI
- 49.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.